TODDE, SERGIO CAMILLO
 Distribuzione geografica
Continente #
NA - Nord America 5.806
EU - Europa 3.220
AS - Asia 1.224
SA - Sud America 124
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 10.398
Nazione #
US - Stati Uniti d'America 5.695
IT - Italia 652
DE - Germania 619
SE - Svezia 464
SG - Singapore 457
CN - Cina 421
RU - Federazione Russa 384
IE - Irlanda 301
UA - Ucraina 227
GB - Regno Unito 178
HK - Hong Kong 159
FI - Finlandia 121
CA - Canada 105
BR - Brasile 93
AT - Austria 74
ID - Indonesia 50
FR - Francia 44
DK - Danimarca 36
NL - Olanda 35
VN - Vietnam 33
IN - India 24
BE - Belgio 21
TR - Turchia 16
JP - Giappone 13
CZ - Repubblica Ceca 12
PL - Polonia 11
AR - Argentina 10
BG - Bulgaria 10
IR - Iran 7
ES - Italia 6
KR - Corea 6
PE - Perù 6
EU - Europa 5
MY - Malesia 5
RO - Romania 5
SA - Arabia Saudita 5
CL - Cile 4
EC - Ecuador 4
ZA - Sudafrica 4
BD - Bangladesh 3
CO - Colombia 3
DO - Repubblica Dominicana 3
IQ - Iraq 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
NO - Norvegia 2
PK - Pakistan 2
SN - Senegal 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
ME - Montenegro 1
MN - Mongolia 1
MU - Mauritius 1
MX - Messico 1
NG - Nigeria 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
Totale 10.398
Città #
Ann Arbor 1.568
Fairfield 433
Houston 372
Woodbridge 359
Wilmington 324
Chandler 321
Ashburn 291
Dublin 284
Singapore 277
Jacksonville 245
Dearborn 194
Frankfurt am Main 192
New York 172
Seattle 165
Santa Clara 161
Hong Kong 150
Milan 142
Cambridge 135
Princeton 112
Munich 94
Nanjing 83
Helsinki 67
Vienna 64
Altamura 59
Shanghai 57
Lawrence 49
Jakarta 44
Beijing 42
Lachine 39
San Diego 34
Council Bluffs 32
Boardman 29
Los Angeles 28
Shenyang 25
Nürnberg 24
Guangzhou 23
Hebei 23
Toronto 23
Brussels 21
Lissone 21
Rome 21
Tianjin 20
Falls Church 19
Nanchang 19
Andover 18
Changsha 17
Dong Ket 17
Fremont 16
Jiaxing 16
Genoa 15
Montréal 15
Ottawa 15
Jinan 14
London 14
Moscow 13
Kunming 11
Ningbo 11
Brno 10
Chicago 10
Edmonton 10
Plovdiv 10
Bologna 9
Naples 9
Padova 9
Auburn Hills 8
Huizen 8
Phoenix 8
São Paulo 8
Carate Brianza 7
Charlottesville 7
Mountain View 7
Norwalk 7
Tokyo 7
Turin 7
Washington 7
Bari 6
Catania 6
Detroit 6
Lima 6
Monza 6
Nuremberg 6
Segrate 6
Taizhou 6
University Park 6
Amsterdam 5
Biassono 5
Chengdu 5
Jyväskylä 5
Newark 5
Philadelphia 5
San Mateo 5
Zhengzhou 5
Assago 4
Borgo Valsugana 4
Cardano al Campo 4
Costa Mesa 4
Hangyang 4
Kiev 4
Pisa 4
Polska 4
Totale 7.323
Nome #
Treatment response assessment in [18F]FDG-PET/CT oncology scans: Impact of count statistics variation and reconstruction protocol 403
Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study 389
Study of the Tissue Distribution of TLQP-21 in Mice Using [18F]JMV5763, a Radiolabeled Analog Prepared via [18F]Aluminum Fluoride Chelation Chemistry 372
Cholinergic ligand [C-11]MP4A: Improved 4-acetoxypiperidine precursor synthesis via LC-APCI/MS characterisation and improved radioligand HPLC purification 332
11C-Labelling of N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential Radioligands for PET imaging of Dopamine D3 Receptors 322
Added diagnostic value of respiratory-gated 4D 18F–FDG PET/CT in the detection of liver lesions: a multicenter study 319
In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416 304
A novel versatile precursor suitable for 18F-radiolabeling via “click chemistry” 286
11C-radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]Zofenoprilat 271
Improved synthesis and radiolabeling of [C-11]MP4A, a suitable ligand for the investigation of the cholinergic system using PET 224
18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer 222
VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells 208
Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation 205
Sperimentazione clinica con radiofarmaci 198
Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma 198
EANM Guideline on the validation of analytical methods for radiopharmaceuticals 197
[11C]RN5: A new agent for the in vivo imaging of myocardial α1-adrenoceptors 186
Radiosynthesis of [123I]βCIT, a selective ligand for the study of the dopaminergic and serotoninergic systems in human brain 186
Synthesis and in vivo evaluation of 3-[C-11]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D-4 receptors antagonist for PET 182
Preparation of [11C]radioligands with high specific radioactivity on a commercial PET tracer synthesizer 180
Development of a bicistronic vector for multimodality imaging of estrogen receptor activity in a breast cancer model: preliminary application 179
Quality Control in the Production of Radiopharmaceuticals 178
Automated production of copper radioisotopes and preparation of high specific activity [(64)Cu]Cu-ATSM for PET studies 173
European regulations for the introduction of novel radiopharmaceuticals in the clinical setting 173
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand 171
Systemic and cerebral kinetics of 16α[18F]fluoro-17β-estradiol: A ligand for the in vivo assessment of estrogen receptor binding parameters 171
Produzione e verifiche di qualità dei radiofarmaci estemporanei per PET e terapia 169
Sensitive GC-MS method for the determination of specific-activity of 16a[18F]Fluoro-estra-1,3,5(10)-triene-3,17b-diol 166
Rsdiofarmaci marcati con fluoro-18 166
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals 162
Synthesis and in vivo evaluation of [C-11]CGP62349, a new GABA(B) receptor antagonist 160
Synthesis and in vivo evaluation of [11C]ICI 118551 as a putative subtype selective β2-adrenergic radioligand 156
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) 155
Intake risk and dose evaluation methods for workers in radiochemistry labs of a medical cyclotron facility 154
Synthesis and carbon-11 labeling of (R)- and (S)-Thionisoxetine, norepinephrine reuptake inhibitors, potential radioligands for Positron Emission Tomography 152
Measurements and evaluation of the risks due to external radiation exposures and to intake of activated elements for operational staff engaged in the maintenance of medical cyclotrons 151
Automation of [C-11]acyl chloride syntheses using commercially available C-11-modules 150
PET imaging and single-cell RNA sequencing glioma microenvironment assessment after RT combined therapy 148
High yield synthesis of [11C]-acetone through selective quenching of methyl lithium 148
Measurement and control of the air contamination generated in a medical cyclotron facility for PET radiopharmaceuticals 145
Synthesis and automated fluorine-18 radiolabeling of new PSMA-617 derivatives with a CuAAC radiosynthetic approach 141
Synthesis and Biodistribution of (R,S)-[O-Methyl-11C]-1-[3-(5-Methoxy-1,2,3,4-Tetrahydro-1-Naphtalenyl)Propyl]-4-Phenylpiperazine (PNU-157760), A Putative Radioligand for 5-HT1A Receptors 140
Labeling and evaluation of N-[11C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors 139
Decommissioning procedures for an 11 MeV self-shielded medical cyclotron after 16 years of working time 138
PET in psychopharmacology 137
Synthesis of [O-methyl-11c]fluvoxamine-a potential serotonin uptake site radioligand 126
Guidance on validation and qualification of processes and operations involving radiopharmaceuticals 126
Clinical Application of a High Sensitivity BGO PET/CT Scanner: Effects of Acquisition Protocols and Reconstruction Parameters on Lesions Quantification 120
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography [2] 119
PET radiopharmacy and automation 114
A PET follow-up study of recovery after stroke in acute aphasics 101
Classificazione ambientale 95
Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals 95
From radiotracer to radiopharmaceutical: a philosophical approach 87
Mild synthesis of [N-methyl-11C]-isovaleroyl-(L)-carnitine. The usefulness of a tritium approach. 85
Guidance on current good radiopharmacypractice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective 84
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals 84
Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [18F]AlF2+ method 78
Highlight selection of radiochemistry and radiopharmacy developments by editorial board 66
Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models 64
EANM guideline on quality risk management for radiopharmaceuticals 59
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals 54
Highlight selection of radiochemistry and radiopharmacy developments by editorial board 53
Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken' 39
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework 34
Totale 10.789
Categoria #
all - tutte 37.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.471


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020242 0 0 0 0 0 0 0 0 0 108 110 24
2020/20211.445 59 71 153 160 117 120 140 112 127 136 106 144
2021/20221.021 89 111 168 136 35 59 62 69 49 59 77 107
2022/20231.344 164 387 84 134 100 197 26 78 71 19 57 27
2023/20241.109 44 40 56 39 147 310 211 40 85 12 8 117
2024/20251.848 137 251 120 98 217 179 202 158 239 247 0 0
Totale 10.789